169 related articles for article (PubMed ID: 30825298)
21. Directed differentiation of induced pluripotent stem cells towards T lymphocytes.
Lei F; Haque R; Xiong X; Song J
J Vis Exp; 2012 May; (63):e3986. PubMed ID: 22617911
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest.
Matsushita H; Hosoi A; Ueha S; Abe J; Fujieda N; Tomura M; Maekawa R; Matsushima K; Ohara O; Kakimi K
Cancer Immunol Res; 2015 Jan; 3(1):26-36. PubMed ID: 25127875
[TBL] [Abstract][Full Text] [Related]
23. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.
Sabzevari H; Reisfeld RA
Cancer Res; 1993 Oct; 53(20):4933-7. PubMed ID: 8402683
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous, delayed-onset killing by multiple-hitting T cells: Stochastic simulations to assess methods for analysis of imaging data.
Beck RJ; Bijker DI; Beltman JB
PLoS Comput Biol; 2020 Jul; 16(7):e1007972. PubMed ID: 32658891
[TBL] [Abstract][Full Text] [Related]
25. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.
Alatrash G; Qiao N; Zhang M; Zope M; Perakis AA; Sukhumalchandra P; Philips AV; Garber HR; Kerros C; St John LS; Khouri MR; Khong H; Clise-Dwyer K; Miller LP; Wolpe S; Overwijk WW; Molldrem JJ; Ma Q; Shpall EJ; Mittendorf EA
Clin Cancer Res; 2019 Apr; 25(8):2610-2620. PubMed ID: 30647079
[TBL] [Abstract][Full Text] [Related]
26. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
Alexander-Miller MA; Leggatt GR; Berzofsky JA
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4102-7. PubMed ID: 8633023
[TBL] [Abstract][Full Text] [Related]
27. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression.
Yang D; Ud Din N; Browning DD; Abrams SI; Liu K
Clin Cancer Res; 2007 Sep; 13(17):5202-10. PubMed ID: 17785576
[TBL] [Abstract][Full Text] [Related]
28. Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma.
Wen M; Xu W; Ren L; Gao F; Cui N; Wen J; Li X; Lin L; Ma Z; Chen B; Cai J
Chin Med J (Engl); 2014; 127(7):1328-33. PubMed ID: 24709189
[TBL] [Abstract][Full Text] [Related]
29. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
30. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
31. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes.
Bendle GM; Holler A; Pang LK; Hsu S; Krampera M; Simpson E; Stauss HJ
Cancer Res; 2004 Nov; 64(21):8052-6. PubMed ID: 15520215
[TBL] [Abstract][Full Text] [Related]
32. Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.
Mehrotra S; Chhabra A; Chattopadhyay S; Dorsky DI; Chakraborty NG; Mukherji B
J Immunol; 2004 Nov; 173(10):6017-24. PubMed ID: 15528336
[TBL] [Abstract][Full Text] [Related]
33. In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity.
Halle S; Keyser KA; Stahl FR; Busche A; Marquardt A; Zheng X; Galla M; Heissmeyer V; Heller K; Boelter J; Wagner K; Bischoff Y; Martens R; Braun A; Werth K; Uvarovskii A; Kempf H; Meyer-Hermann M; Arens R; Kremer M; Sutter G; Messerle M; Förster R
Immunity; 2016 Feb; 44(2):233-45. PubMed ID: 26872694
[TBL] [Abstract][Full Text] [Related]
34. Two distinct populations of primary cytotoxic cells infiltrating into allografted tumor rejection sites: infiltration of macrophages cytotoxic against allografted tumor precedes that of multiple sets of cytotoxic T lymphocytes with distinct specificity to alloantigens.
Yoshida R; Matsuura A; Einaga K; Ushio Y; Yamamoto N; Yoneda Y
Microbiol Immunol; 1997; 41(2):149-59. PubMed ID: 9087957
[TBL] [Abstract][Full Text] [Related]
35. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
[TBL] [Abstract][Full Text] [Related]
36. Individual Human Cytotoxic T Lymphocytes Exhibit Intraclonal Heterogeneity during Sustained Killing.
Vasconcelos Z; Müller S; Guipouy D; Yu W; Christophe C; Gadat S; Valitutti S; Dupré L
Cell Rep; 2015 Jun; 11(9):1474-85. PubMed ID: 26027932
[TBL] [Abstract][Full Text] [Related]
37. Cx43-Gap Junctions Accumulate at the Cytotoxic Immunological Synapse Enabling Cytotoxic T Lymphocyte Melanoma Cell Killing.
Hofmann F; Navarrete M; Álvarez J; Guerrero I; Gleisner MA; Tittarelli A; Salazar-Onfray F
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547237
[TBL] [Abstract][Full Text] [Related]
38. Contact-Dependent Killing by Cytotoxic T Lymphocytes Is Insufficient for EL4 Tumor Regression
Beck RJ; Slagter M; Beltman JB
Cancer Res; 2019 Jul; 79(13):3406-3416. PubMed ID: 31040155
[TBL] [Abstract][Full Text] [Related]
39. Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.
Haque M; Song J; Fino K; Sandhu P; Wang Y; Ni B; Fang D; Song J
Cell Transplant; 2016; 25(5):811-27. PubMed ID: 26777320
[TBL] [Abstract][Full Text] [Related]
40. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
